Xanomeline and Trospium Chloride Capsules + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
May 29, 2023 → Dec 9, 2024
NCT ID
NCT05919823About Xanomeline and Trospium Chloride Capsules + Placebo
Xanomeline and Trospium Chloride Capsules + Placebo is a phase 3 stage product being developed by Zai Lab for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT05919823. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05919823 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia